Evidence map›Paper›PMID 41703168›Full record

ArticleScientific reports2026

Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions.

Nattha Ingavat, Yee Jiun Kok, Nuruljannah Dzulkiflie, Liew Jia Min, Wang Xinhui, Kia Ngee Low, Ka Pui But, Amihan Anajao, Loh Han Ping, Han Kee Ong and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nattha Ingavat *Downstream Processing Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Yee Jiun Kok *Protein Analytics Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Nuruljannah DzulkiflieDownstream Processing Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Liew Jia MinDownstream Processing Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Wang XinhuiDownstream Processing Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Kia Ngee LowProtein Analytics Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Ka Pui ButProtein Analytics Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Amihan AnajaoProtein Analytics Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Loh Han PingCell Line Development Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Han Kee OngCell Line Development Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Farouq Bin MahfutCell Line Development Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Yuansheng YangCell Line Development Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore.
Xuezhi BiProtein Analytics Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore. bi_xuezhi@a-star.edu.sg.
Wei ZhangDownstream Processing Group, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, 138668, Republic of Singapore. zhang_wei@a-star.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over recent decades, bispecific antibodies (bsAbs) have garnered significant attention for their superior therapeutic efficacy compared to progenitor monoclonal antibodies, enabling innovative treatment strategies. Despite their potential, the development of bsAbs presents significant challenges, with structural stability playing a pivotal role in manufacturability, therapeutic performance, and safety. Among the factors influencing stability, the design and incorporation of molecular linkers are particularly critical. In this study, we investigated the structural stability and fragmentation profiles of a symmetric bispecific antibody (Sym-bsAb), targeting HER2 and CD3, under forced degradation conditions. The Sym-bsAb exhibited pronounced fragmentation under prolonged thermal stress, particularly when combined with high pH and salt conditions. Intact mass analysis identified key degradation events, including sequential clipping along G4S and G4 linkers, fragmentations at interchain cystinyl residues and cleavage at the C-terminal of asparagine residues. The identification of G4S and G4 linkers as vulnerable regions prone to clipping in Sym-bsAb provided valuable insights into the stability and manufacturability of bsAbs incorporating linker sequences, underscoring critical considerations for their development.

Indexed as

Antibodies, BispecificCD3 ComplexErb-b2 Receptor Tyrosine KinasesHumansHydrogen-Ion ConcentrationProtein StabilityAntibodies, BispecificCD3 ComplexERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAntibody fragmentationG4 linkerG4S linkerStructural stabilitySymmetric bispecific antibodies

Identifiers

PMID41703168
PMCPMC13013917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.